Stock Alert: Rhythm (RYTM) Trades 5.81% Lower May 13

Equities Staff  |

Today, Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) was down $0.2 to finish the day Friday at $3.24.

The company opened at $3.44 and shares fluctuated between $3.55 and $3.17 with 992,252 shares trading hands.

Rhythm is averaging 402,266 shares traded over the last 30 days. They have shed 65.53% YTD.

Rhythm expects its next earnings on 2022-08-02.

For technical charts, analysis, and more on Rhythm visit the company profile.

About Rhythm Pharmaceuticals Inc.

Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within the melanocortin-4 receptor (MC4R) pathway, a key hypothalamic pathway that regulates hunger, caloric intake, and energy expenditure, consequently affecting body weight. Rhythm is developing setmelanotide for the treatment of rare genetic diseases of obesity that arise due to an impaired pathway, as setmelanotide has shown the potential to restore impaired pathway function.

To get more information on Rhythm Pharmaceuticals Inc. and to follow the company's latest updates, you can visit the company's profile page here: Rhythm Pharmaceuticals Inc.'s Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Big Lots Down 18% in Premarket Trading Friday on Surprise Missed Earnings
Modine Posts Strong Rebound in Fiscal Q4, Raises 2023 Guidance
Dollar Tree Posts Record First Quarter, Leads Nasdaq Gainers
Kohl's Still in Play To Be Acquired
Chinook Therapeutics Raises $105 Million for Kidney Disease Therapies
Market Conditions Driving Higher Base Level for VIX Volatility Index
Will New AT&T, Dish Co-opetition Deal Work: Jeff Kagan
Cisco Down 12% in Premarket Trading Thursday After Top Line Miss and Lower Forecast



Market Movers

Sponsored Financial Content